Andrew P. Sage

Andrew P. Sage

Auto-generated profile, based on publicly available information

Andrew P. Sage

Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2013 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YZYasmine Zouggari
Yasmine Zouggari
HAHafid Ait-Oufella
Hafid Ait-Oufella
PBPhilippe Bonnin
Philippe Bonnin
TSTabassome Simon
Tabassome Simon
ASAndrew P Sage
Andrew P Sage
ZMZiad Mallat
Ziad Mallat

27 July 2010 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
ASAndrew P. Sage
Andrew P. Sage
YTYin Tintut
Yin Tintut
LDLinda Demer
Linda Demer

8 November 2018 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
ASAndrew P. Sage
Andrew P. Sage
DTDimitrios Tsiantoulas
Dimitrios Tsiantoulas
CBChristoph J. Binder
Christoph J. Binder
ZMZiad Mallat
Ziad Mallat

1 February 2011 in Kidney International
Verified
Journal Article
Closed access
PDF file
ASAndrew P. Sage
Andrew P. Sage
JLJinxiu Lu
Jinxiu Lu
YTYin Tintut
Yin Tintut
LDLinda Demer
Linda Demer

9 May 2014 in Circulation Research
Verified
Journal Article
Open access
PDF file
HAHafid Ait-Oufella
Hafid Ait-Oufella
ASAndrew P. Sage
Andrew P. Sage
ZMZiad Mallat
Ziad Mallat
ATAlain Tedgui
Alain Tedgui
Chronic inflammation in response to lipoprotein accumulation in the arterial wall is central in the development of atherosclerosis. Both innate and adaptive immunity are involved in this process. Adaptive immune responses develop against an array of potential antigens presented to effector T lymphocytes by antigen-presenting cells, especially dendritic cells. Functional analysis of the role of different T-cell subsets identified the Th1 responses as proatherogenic, whereas regulatory T-cell responses exert antiatherogenic activities. The effect of Th2 and Th17 responses is still debated. Atherosclerosis is also associated with B-cell activation. Recent evidence established that conventional B-2 cells promote atherosclerosis. In contrast, innate B-1 B cells offer protection through secretion of natural IgM antibodies. This review discusses the recent development in our understanding of the role of T- and B-cell subsets in atherosclerosis and addresses the role of dendritic cell subpopulations in the control of adaptive immunity.

13 October 2008 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
MAMasih-Ul Alam
Masih-Ul Alam
JKJohn Paul Kirton
John Paul Kirton
FWFiona L. Wilkinson
Fiona L. Wilkinson
ETEmily Towers
Emily Towers
SSSmeeta Sinha
Smeeta Sinha
ACAnn E. Canfield
Ann E. Canfield
Vascular calcification (VC) is highly correlated with increased morbidity and mortality in advanced chronic kidney disease (CKD) patients. Allosteric modulation of the calcium-sensing receptor (CaR) by calcimimetics inhibits VC in animal models of advanced CKD. Here, we investigated the expression of the CaR in the vasculature and tested the ability of calcimimetics to prevent vascular smooth muscle cell (VSMC) calcification in vitro. Immunohistochemical staining demonstrated that CaR protein is present in VSMC in normal, non-calcified human arteries. In contrast, low levels of CaR immunoreactivity were detected in atherosclerotic, calcified arteries. Immunfluorescence and immunoblotting revealed that CaR protein was also expressed by human and bovine VSMC in vitro. Acute stimulation of VSMC with increased Ca2+ stimulated extracellular signal-regulated kinase (ERK1/2) phosphorylation, suggesting that the VSMC CaR is functional. VSMC CaR expression decreased when these cells deposited a mineralized matrix or following 24 h incubation in mineralization medium with increased (i.e. 1.8 or 2.5 mM) Ca2+. Culturing VSMC in mineralization medium containing 1.8 and 2.5 mM Ca2+ or with the membrane-impermeant CaR agonist Gd3+ enhanced mineral deposition compared with that observed in 1.2 mM Ca2+. Over-expression of dominant-negative (R185Q) CaR enhanced, whereas the calcimimetic R-568 attenuated, VSMC mineral deposition. These results demonstrate that: (i) VSMCs express a functional CaR; (ii) a reduction in CaR expression is associated with increased mineralization in vivo and in vitro; (iii) calcimimetics decrease mineral deposition by VSMC. These data suggest that calcimimetics may inhibit the development of VC in CKD patients.